Over a few weeks, patterns emerge
Instead, people often describe: Feeling full sooner during meals Hunger returning more slowly Less intense cravings Easier decision-making around food This is because semaglutide slows digestion and influences hunger signaling in the brain, helping appetite feel more manageable rather than overwhelming
The senior author, Shirley Wang, PhD, stated the aim of a transparent project was to allow for scientific merit regardless of outcome, and omitted barriers to engagement by preregistering their project and sharing data analytic code
Cagrilintide vs tirzepatide (Mounjaro/Zepbound) Mechanism: Cagrilintide: Amylin agonist Tirzepatide: Dual GIP/GLP-1 agonist Both novel approaches Weight loss: Cagrilintide: 10-12% monotherapy Tirzepatide: 15-22% monotherapy Tirzepatide superior as single agent Administration: Both: Weekly subcutaneous injection Both: Similar convenience Side effects: Cagrilintide: Strong GI effects Tirzepatide: Moderate GI effects Similar overall profile Approval status: Cagrilintide: Investigational Tirzepatide: FDA approved Tirzepatide available now Cost (when both available): Likely similar ($1,000-1,500/month) Both premium weight loss options Verdict: Currently, tirzepatide better choice (approved, superior weight loss)
Management is supportive
